4
-
4E-BP1
-
4E-binding protein1
5
-
5-FU
-
5-fluorouracil
-
5-FUTP
-
5-fluorouridine triphosphate
-
5-HT
-
5-hydroxytryptamine
-
5HRE
-
hypoxia-response element
A
-
Ab
-
antibody
-
ABCB1
-
ATP-binding cassette protein B1
-
ABCC2
-
ATP-binding cassette protein C2
-
ABCG2
-
ATP-binding cassette protein G2
-
ACE
-
angiotensin converting enzyme
-
ACT
-
adaptive cell transfer
-
ACTH
-
adrenocorticotropic hormone
-
ADC
-
adenocarcinoma
-
ADCC
-
antibody-dependent cellular cytotoxicity
-
ADL
-
activities of daily living
-
AEE
-
activity-induced energy expenditure: the energy spent on physical activity
-
AFP
-
alpha-fetoprotein
-
Ag
-
antigen
-
AI
-
aromatase inhibitor
-
AICR
-
American Institute for Cancer Research
-
AIHA
-
autoimmune haemolytic anaemia
-
AIS
-
adenocarcinoma in situ
-
AITL
-
angioimmunoblastic T-cell lymphoma
-
ALC
-
absolute lymphocyte count
-
ALCL
-
anaplastic large-cell lymphoma
-
ALDH
-
aldehyde dehydrogenases
-
ALK
-
anaplastic lymphoma kinase
-
ALT
-
alanine aminotransferase
-
AML
-
acute myeloid leukaemia (also, acute myelogenous leukaemia and acute myeloblastic leukaemia)
-
AMPK
-
adenosine 5’-monophosphate-activated protein kinase
-
ANC
-
absolute neutrophil count
-
Ang
-
Angiopoietins
-
AP
-
alkaline phosphatase
-
Apaf1
-
apoptotic protease activating factor 1
-
APC
-
adenomatous polyposis coli
-
APCs
-
antigen-presenting cells
-
APL
-
acute promyelocytic leukaemia
-
AQUA
-
automated quantitative protein expression analysis
-
AR
-
androgen receptor
-
Ara-C
-
cytarabine
-
Ara-CDP
-
Ara-C diphosphate
-
Ara-CMP
-
Ara-C monophosphate
-
Ara-CTP
-
Ara-C triphosphate
-
ARF
-
ADP ribosylation factor
-
Array-CGH
-
microarray-based comparative genomic hybridisation
-
ASA404
-
vadimezan
-
ASCT
-
autologous stem cell transplantation
-
AST
-
aspartate aminotransferase
-
ATE
-
arterial thrombotic event
-
ATO
-
arsenic trioxide
-
ATP
-
adenosine triphosphate
-
ATR
-
ataxia telangiectasia and Rad3-related
-
ATRA
-
tretinoin (all-trans-retinoic acid)
-
AUC
-
area under the curve. A representation of total drug exposure. The area-under-the-curve is a function of (1) the length of time the drug is present, and (2) the concentration of the drug in blood plasma.
-
ASC
-
Area della superficie corporea.
B
-
BAL
-
bronchoalveolar lavage
-
BBB
-
blood-brain barrier
-
BC
-
breast cancer
-
BCL7A
-
B-cell CLL/lymphoma 7A
-
Bcr
-
B-cell receptor
-
BCRP
-
breast cancer resistance protein
-
BCS
-
breast conserving surgery
-
BER
-
base excision repair
-
BFGF
-
basic fibroblast growth factor 2
-
BH3
-
Bcl-2 homology 3
-
BHLH
-
basic helix–loop–helix
-
BIA
-
bioimpedance analysis
-
B.i.d.
-
Due volte al giorno.
-
BL
-
Burkitt lymphoma
-
BM
-
bone marrow
-
BMI
-
body mass index = body weight (kg) /body height (m2)
-
BP
-
blood pressure
-
BSC
-
best supportive care
-
BUN
-
blood urea nitrogen
C
-
C.i.
-
continuous infusion
-
CA4P
-
combretastatin A4 phosphate
-
CBCL
-
cutaneous B-cell lymphoma
-
CBP
-
CREB-binding protein
-
CD
-
cluster of differentiation
-
Cd-AMP
-
cladribine monophosphate
-
Cd-ATP
-
cladribine triphosphate
-
CDC
-
complement-dependent cytotoxicity
-
CDDP
-
cisplatin
-
CDKI
-
cyclin-dependent kinase inhibitors
-
CEA
-
carcinoembryonic antigen
-
CEC
-
circulating endothelial cell
-
CEP17
-
chromosome 17 centromere
-
CGH
-
comparative genomic hybridisation
-
CHF
-
congestive heart failure
-
CHO
-
carbohydrates
-
CI
-
confidence interval
-
CIS
-
carcinoma in situ
-
CISH
-
chromogenic in situ hybridisation
-
CK-19
-
cytokeratin-19
-
CKI
-
cyclin-dependent kinase inhibitors
-
Cl
-
clearance
-
CLL
-
chronic lymphocytic leukaemia
-
ClTB
-
total body clearance
-
Cmax
-
peak concentration
-
CML
-
chronic myeloid leukaemia (also, chronic myelogenous leukaemia and chronic myeloblastic leukaemia)
-
CMML
-
chronic myelomonocytic leukaemia
-
CMV
-
cytomegalovirus
-
CNS
-
central nervous system
-
COMT
-
catechol-omethyltransferase
-
COPD
-
chronic obstructive pulmonary disease
-
COX
-
cyclooxygenase
-
CP
-
chronic phase
-
CPA
-
cyclophosphamide
-
CPE
-
cytopathic effect
-
CPK
-
creatine phosphokinase
-
CPT
-
camptothecin
-
CR
-
complete response
-
CRC
-
colorectal cancer
-
CREB
-
cyclic AMP response-element binding protein
-
CSCC
-
cutaneous squamous cell carcinoma
-
CSF
-
colony-stimulating factor
-
CSF1R
-
colony stimulating factor 1 receptor
-
Css
-
average steady state concentration
-
CT
-
computed tomography
-
CTCAE
-
Common Terminology Criteria for Adverse Events (CTCAE), developed by the National Cancer Institute (NCI) of the United States of America, is a regularly updated document that provides a standard chart for reporting the severity of adverse events occurring in cancer clinical trials. Despite its widespread use and its utility, the CTCAE has not been validated, and more specific scales may be used for some adverse events.
-
CTCL
-
cutaneous T-cell lymphoma
-
CTGF
-
connective-tissue growth factor
-
CUP
-
cancer of unknown primary
D
-
D-TMP
-
deoxythymidine monophosphate
-
DAPK
-
death-associated protein kinase
-
DC
-
dendritic cell
-
DCE-MRI
-
dynamic contrast-enhanced MRI
-
DCK
-
deoxycytidine kinase
-
DEE
-
diet-induced energy expenditure: the energy spent to digest and absorb nutrients
-
Del
-
deletion
-
DEXA
-
dual-energy X-ray absorptiometry
-
DFS
-
disease-free survival
-
DGGE
-
denaturing gradient gel electrophoresis
-
DHAD
-
mitoxantrone
-
DHFR
-
dihydrofolate reductase
-
DIC
-
disseminated intravascular coagulation
-
DISC
-
death-inducing signaling complex
-
DLBCL
-
diffuse large B-cell lymphoma
-
DLCO
-
diffusing capacity for carbon monoxide
-
DLT
-
dose-limiting toxicity
-
DM
-
diabetes mellitus
-
DMH
-
differential methylation hybridisation
-
DNMT
-
DNA methyltransferase
-
DNMTi
-
DNA methyltransferase inhibitor
-
DNR
-
daunorubicin
-
DNR-OL
-
daunorubicinol
-
DOX
-
doxorubicin
-
DPD
-
dihydropyrimidine dehydrogenase
-
DSB
-
double-strand break
-
DTC
-
disseminated tumour cell
-
DUSP1
-
dual specificity phosphatase 1
-
DUSP4
-
dual specificity protein phosphatase 4
-
DVT
-
deep vein thrombosis
-
DXM
-
dexamethasone
E
-
E1
-
oestrone
-
E2
-
estradiol
-
EATL
-
enteropathy associated T-cell lymphoma
-
EBER
-
Epstein-Barr early RNA
-
EBUS
-
endobronchial ultrasound
-
EBV
-
Epstein-Barr virus
-
ECG
-
electrocardiogram: A medical test of the electrical activity of a patient's heart.
-
ECM
-
extracellular matrix
-
ECs
-
endothelial cells
-
EFS
-
event-free survival
-
EGF
-
Fattore di crescita epidermico (EGF): Fattore di crescita proteico (6 KDa, 53 amminoacidi) che si lega al recettore del fattore di crescita epidermico. Il legame dell’EGF attiva vie metaboliche specifiche della crescita cellulare in alcune cellule cancerose e anche in alcune cellule normali.
-
EGFR
-
Recettore del fattore di crescita epidermico (EGFR)
Proteina che si trova sulla superficie della maggior parte delle cellule epiteliali e alla quale si lega il fattore di crescita epidermico, innescando una cascata di segnali all’interno della cellula, il cui risultato finale è l’induzione della divisione cellulare. -
EGFRI
-
Inibitori del recettore per il fattore di crescita epidermico (EGFRI): Farmaci che hanno come bersaglio l’EGFR e lo inibiscono, inclusi gli anticorpi monoclonali e gli inibitori a basso peso molecolare della tirosin chinasi.
-
EIA
-
enzymo-immunoassay
-
EMA
-
The European Medicines Agency (EMA) is a European Union agency, responsible for the scientific evaluation and registration of medicines mainly for use in the European Union.
-
EML4
-
echinoderm microtubule associated protein like 4
-
EN
-
enteral nutrition
-
EOD-CS
-
early-onset diarrhoea-cholinergic syndrome
-
EOT
-
end of treatment
-
EPI
-
epirubicin
-
EPI-OL
-
epirubicinol
-
EPO
-
erythropoietin
-
EpoR
-
erythropoietin receptor
-
EPP
-
extrapleural pneumonectomy
-
ER
-
oestrogen receptor
-
ERCC
-
excision repair cross complement
-
ERG
-
ETS-related gene
-
ESPEN
-
European Society for Clinical Nutrition and Metabolism
-
EUS
-
endoscopic ultrasound
-
E.v.
-
Endovenoso, per via endovenosa.
F
-
FAA
-
flavone acetic acid
-
FAK
-
focal adhesion kinase
-
FDA
-
Food and Drug Administration
-
FDG
-
F-18-Fluorodeoxyglucose
-
FEV1%pred
-
predicted % forced expiratory volume in 1 minute
-
FFPE
-
formalin-fixed, paraffin-embedded
-
FFS
-
failure free survival
-
FGF
-
fibroblastic growth factor
-
FGFR
-
fibroblast growth factor receptor
-
FH2
-
dihydrofolic acid
-
FH4
-
tetrahydrofolic acid
-
FL
-
follicular lymphoma
-
FN
-
febrile neutropenia
-
FNA
-
fine needle aspiration
-
FPE
-
fixed paraffin embedded
-
FRs
-
framework regions
-
FSH
-
follicle stimulating hormone
-
FT
-
farnesyltransferase
-
FVIII-RA
-
factor VIII-related antigen
-
FPS
-
Fattore di protezione solare (FPS): È noto anche con la sigla FPS e indica il fattore di estensione della protezione contro i raggi UVB mediante uso di prodotti specifici per la filtrazione dei raggi solari.
G
-
G-CSF
-
granulocyte-colony stimulating factor
-
GABA
-
gamma-aminobutyric acid
-
GEP
-
gastroenteropancreatic
-
GFAP
-
glial fibrillary acidic protein
-
GFR
-
glomerular filtration rate
-
GI
-
gastrointestinal
-
GI50
-
growth inhibition of 50% of cells
-
GIST
-
gastrointestinal stromal tumour: a rare type of sarcoma found most often in the wall of the stomach.
-
GnRH
-
gonadotropin-releasing hormone
-
GPCRs
-
G protein-coupled receptors
-
Grb2
-
growth factor receptor-bound protein 2
-
GRB7
-
gene encoding growth factor receptor-bound protein 7
-
GRFT
-
glycinamide ribonucleotide formyl transferase
-
Gy
-
gray
H
-
H&N
-
head and neck
-
HAART
-
highly active antiretroviral therapy
-
HAT
-
histone acetyltransferase
-
HBV
-
hepatitis B virus
-
HCG
-
human chorionic gonadotropin
-
HCV
-
hepatitis C virus
-
HD
-
high dose
-
HDAC
-
histone deacetylase
-
HDACi
-
HDAC inhibitor
-
HDT
-
high-dose therapy
-
HFS
-
hand–foot syndrome
-
HGF
-
hepatocyte growth factor
-
HIF
-
hypoxia-inducible factors
-
HIV
-
human immunodeficiency virus
-
HL
-
Hodgkin lymphoma
-
HLA
-
human leukocyte antigen
-
HNSCC
-
head and neck squamous cell carcinoma
-
HP1
-
heterochromatin protein 1
-
HPF
-
high-power field
-
HPV
-
human papilloma virus
-
HR
-
hazard ratio
-
HRQoL
-
health-related quality of life
-
HRR
-
homologous recombination repair
-
HSCT
-
haematopoietic stem cell transplantation
-
HSR
-
hypersensitivity reaction
-
HSTL
-
hepatosplenic T-cell lymphoma
-
HU
-
hydroxyurea
-
HUS
-
hemolytic–uremic syndrome
O
-
OS
-
Operatore sanitario.
-
ONS
-
oral nutritional supplementation
-
ORR
-
overall response rate
-
OS
-
overall survival
I
-
I-CAM
-
intercellular cell adhesion molecule
-
IARC
-
International Agency for Research on Cancer
-
IC50
-
concentration at which growth/activity is inhibited by 50%
-
IDA
-
idarubicin
-
IDMS
-
isotope dilution mass spectroscopy
-
IDOL
-
idarubicinol
-
IFN
-
interferon
-
IFN-γ
-
interferon gamma
-
IFNAR
-
IFN-α receptor
-
Ig
-
immunoglobulin
-
IGF
-
insulin growth factor
-
IGF-1R
-
insulin-like growth factor-1 receptor
-
IGFBP
-
insulin-like growth factor-binding protein
-
IGFBP-3
-
insulin-like growth factor-binding protein-3
-
IGFBPs
-
IGF-binding proteins
-
IHC
-
immunohistochemistry
-
IL
-
interleukin
-
ILK
-
integrin-linked kinase
-
IM
-
intramuscular
-
IMiD
-
immunomodulatory drug
-
IMRT
-
intensity modulated radiotherapy
-
IND
-
investigational new drug
-
INR
-
international normalised ratio: a measure of the time it takes for blood to clot.
-
InsR
-
insulin receptor
-
IP
-
intraperitoneal
-
IPD
-
individual patient-based
-
IPI
-
international prognostic index
-
IPS
-
International prognostic score
-
IPSS
-
International Prognostic Scoring System
-
IRS
-
inflammatory response syndrome
-
ISG
-
interferon stimulating genes
-
ISH
-
in situ hybridisation
-
ITMIG
-
International Thymic Malignancy Interest Group
J
-
JAK
-
Janus kinase
K
-
KLF6
-
Kruppel-like factor 6
-
KS
-
Kaposi’s sarcoma
L
-
LC50
-
cytotoxic killing of 50% of cells
-
LCNEC
-
large cell neuroendocrine carcinoma
-
LD10
-
lethal dose to 10% of animals
-
LDCT
-
low-dose computed tomography
-
LDH
-
lactose dehydrogenase
-
LFT
-
liver function test
-
LH
-
luteinising hormone
-
LINAC
-
linear accelerator
-
LL
-
lymphoblastic lymphoma
-
LLN
-
lower limit of normal
-
LMP 1
-
latent membrane protein 1
-
LMWH
-
low molecular weight heparin
-
LN
-
lymph node
-
LOD
-
late-onset diarrhoea
-
LOH
-
loss of heterozygosity
-
LP
-
lumbar puncture
-
LPL
-
lymphoplasmacytic lymphoma
-
LT
-
lymphoid tissue
-
LTB4
-
leukotriene B4
-
LV
-
leucovorin
-
LVEF
-
left ventricular ejection fraction
M
-
M-AMSA
-
amsacrine
-
M-CGH
-
metaphase comparative genomic hybridisation
-
M-CSF
-
macrophage colony-stimulating factor
-
MAb
-
monoclonal antibody
-
MAOI
-
monoamine oxidase inhibitors
-
MAP
-
mitogen-activated protein
-
MAPK
-
mitogen-activated protein kinase
-
MBPs
-
methyl-CpG binding proteins
-
MCL
-
mantle cell lymphoma
-
MCM
-
minichromosome maintenance
-
MCP1
-
monocyte chemoattractant protein-1
-
MCRC
-
metastatic colorectal cancer
-
MDP
-
myeloproliferative disease
-
MDR
-
multidrug resistance
-
MDS
-
myelodysplastic syndrome
-
MEK
-
mitogen-activated protein kinase
-
MEN-1
-
multiple endocrine neoplasia type 1
-
MGUS
-
monoclonal gammopathy of undetermined significance
-
MHC
-
major histocompatibility complex
-
MHC class I
-
major histocompatibility complex I
-
MHC class II
-
major histocompatibility complex II
-
MITF
-
microphthalmia-associated transcription factor
-
MIU
-
million international units
-
MLH1
-
mutL homolog 1
-
MLPC
-
mixed lymphocyte-peptide culture
-
MMAE
-
monomethylauristatin E
-
MMPs
-
matrix metalloproteinases
-
MMR
-
mismatch-repair genes
-
MMT
-
multimodality treatment
-
MORF
-
MOZ-related factor
-
MOZ
-
monocytic leukemia zinc-finger protein
-
MPM
-
malignant pleural mesothelioma
-
MRCC
-
metastatic renal cell cancer
-
MRI
-
magnetic resonance imaging
-
MRP
-
multidrug-resistance protein
-
MSI
-
Microsatellite instability
-
MSP
-
methylation-specific polymerase chain reaction
-
MTD
-
maximum tolerated dose
-
MTOR
-
mammalian target of rapamycin
-
MTX
-
methotrexate
-
MUGA
-
multigated acquisition
-
MW
-
molecular weight
-
MZL
-
marginal zone lymphoma
N
-
N-CoR
-
nuclear receptor corepressor
-
NAChR
-
nicotinic acetylcholine receptor
-
NCI
-
National Cancer Institute
-
ND
-
not done
-
Neg
-
negative
-
NER
-
nucleotide excision repair
-
NET
-
neuroendocrine tumour
-
NF-κB
-
nuclear factor κ B
-
NHL
-
non-Hodgkin lymphoma
-
NK
-
natural killer
-
NK cell
-
natural killer cell
-
NLPHL
-
nodular lymphocyte-predominant Hodgkin lymphoma
-
NOS
-
nitric oxide synthase
-
NPY
-
neuropeptide Y
-
NRP-1
-
neuropilin 1
-
NRT
-
nicotine replacement therapy
-
NSAID
-
non-steroidal anti-inflammatory drug
-
NSCLC
-
non-small-cell lung cancer
-
NSE
-
neurone-specific enolase
-
NV
-
normal value
P
-
P.o.
-
per os, orally
-
P/D
-
pleurectomy/decortication
-
PAHs
-
polycyclic aromatic hydrocarbons
-
PAI-1
-
plasminogen activator inhibitor
-
PARP
-
poly ADP-ribose polymerase
-
PARs
-
protease-activated receptors
-
PB
-
peripheral blood
-
PBSC
-
peripheral blood stem cell
-
PCI
-
prophylactic cranial irradiation
-
PCR-RFLP
-
polymerase chain reaction restriction
-
PD
-
progressive disease
-
PDCD5
-
programmed cell death 5
-
PDGF
-
platelet-derived growth factor: a regulator of cell division.
-
PDGFR
-
platelet-derived growth factor receptor: a form of tyrosine kinase receptor that receives PDGF.
-
PDK1
-
phosphoinositide-dependent kinase 1
-
PDN
-
prednisolone
-
PEG
-
pegylated
-
PET
-
positron emission tomography
-
PFS
-
progression-free survival
-
PgP
-
P-glycoprotein
-
PgR
-
progesterone receptor
-
Ph+
-
Philadelphia chromosome-positive
-
PIF
-
interstitial fluid pressure
-
PIP2
-
phosphatidylinositol-4,5-bisphosphate
-
PK
-
pharmacokinetics
-
PKB
-
protein kinase
-
PLD
-
pegylated liposomal doxorubicin
-
PlGF
-
placenta growth factor
-
PLT
-
platelet
-
PLZF
-
promyelocytic leukaemia zinc finger
-
PML
-
promyelocytic leukaemia
-
PN
-
parenteral nutrition
-
PNET
-
pancreatic neuroendocrine tumour
-
PORT
-
postoperative radiotherapy
-
Pos
-
positive
-
PPE
-
palmar–plantar erythrodysesthesia
-
PR
-
partial response
-
PT
-
prothrombin time
-
PTCL
-
peripheral T-cell lymphoma
-
PTD
-
protein transduction domain
-
PTEN
-
phosphatase and tensin homologue
-
PTH
-
parathyroid hormone
-
PTPRG
-
protein tyrosine phosphatase receptor gamma
Q
-
Q-RT-PCR
-
quantitative real-time polymerase chain reaction
-
QALY
-
quality-adjusted life years
-
Q.d.
-
Una volta al giorno.
-
QoL
-
quality of life
-
QPCR
-
quantitative polymerase chain reaction
-
QTc
-
Corrected QT interval, a measure of QT interval corrected for heart rate extremes.
R
-
RA-APL
-
retinoic acid–antiphospholipid syndrome
-
Raptor
-
regulatory associated protein of mTOR
-
RARs
-
retinoic acid receptors
-
RARα
-
retinoic acid receptor alpha
-
RARβ2
-
retinoic acid receptor beta-2
-
RASSF1A
-
Ras association domain family member 1A
-
RBC
-
red blood cell
-
RCC
-
renal cell carcinoma
-
RCT
-
randomised controlled trials
-
REE
-
resting energy expenditure: the energy needed to preserve basic vital functions
-
Rheb
-
Ras homolog enriched in brain
-
RIA
-
radioimmunoassay
-
RIC
-
reduced-intensity conditioning regimen
-
RNAi
-
RNA interference
-
RNR
-
ribonucleotide reductase
-
ROC
-
receiver operating characteristic
-
RPLS
-
reversible posterior leukoencephalopathy syndrome
-
RR
-
response rate
-
RRM1
-
ribonucleotide reductase
-
RT
-
radiotherapy
-
RTK
-
receptor tyrosine kinase
-
RXR
-
retinoid X receptor
S
-
S6K
-
ribosomal S6 kinase
-
SABR
-
stereotactic ablative radiotherapy
-
SBM
-
solitary brain metastasis
-
SC
-
subcutaneous
-
SCCHN
-
squamous cell carcinoma of the head and neck
-
SCF
-
stem-cell factor
-
SCLC
-
small-cell lung cancer
-
SD
-
stable disease
-
SELDI-TOF-MS
-
surface-enhanced laser desorption and ionisation–time of flight mass spectrometry
-
SERMs
-
selective oestrogen receptor modulators
-
SH2
-
Src-homology 2
-
SHBG
-
sex hormone-binding globulin
-
ShRNA
-
short hairpin RNA; short-interfering hairpin
-
SIADH
-
syndrome of inappropriate antidiuretic hormone
-
SINEs
-
short interspersed elements
-
SIRS
-
systemic inflammatory response syndrome
-
SLAM
-
signalling lymphocytic activation molecule
-
SLN
-
sentinel lymph node
-
SMRT
-
silencing mediator of retinoid and thyroid receptors
-
SNP
-
single nucleotide polymorphism
-
SOCS
-
suppressor of cytokine signalling
-
SPC
-
summary of product characteristics
-
SPN
-
solitary pulmonary nodule
-
SPTCL
-
subcutaneous panniculitis-like T-cell lymphoma
-
SQCC
-
squamous cell carcinoma
-
SR
-
sleeve resection
-
SSB
-
single-strand break
-
SST
-
superior sulcus tumour
-
SUV
-
standardised uptake volume
T
-
T1/2
-
half-life
-
TBNA
-
transbronchial needle biopsy
-
TBP2
-
thioredoxin-binding protein 2
-
TC
-
typical carcinoid
-
TCR
-
T-cell receptor
-
TDL
-
lowest dose that results in no toxicity
-
TE
-
thromboembolism
-
TEE
-
thromboembolic event
-
TF
-
tube feeding
-
TFAP
-
transcriptional factor AP-2 α
-
TFPI
-
tissue factor pathway inhibitor
-
TGF
-
transforming growth factor
-
TGF-α
-
transforming growth factor-α
-
TGF-β
-
transforming growth factor-β
-
TGI
-
total growth inhibition
-
T.i.d.
-
Tre volte al giorno.
-
TIL
-
tumour infiltrating lymphocytes
-
TIMP
-
tissue inhibitor of metalloproteinases
-
TKI
-
tyrosine kinase inhibitor
-
Tmax
-
time to peak concentration
-
TMS1
-
target of methylation-induced silencing
-
TNBC
-
triple negative breast cancer
-
TNF
-
tumour necrosis factor
-
TNF-α
-
tumour necrosis factor-α
-
TNM
-
tumour, lymph nodes, distant metastases classification
-
TOP1ccs
-
topo-I cleavable complex
-
Topo
-
topoisomerase
-
TPC
-
tunnelled pleural catheter
-
TPN
-
total parental nutrition
-
TRAIL
-
TNF-related apoptosis-inducing ligand
-
TS
-
thymidylate synthase
-
TSC
-
tuberous sclerosis
-
TSH
-
thyroid stimulating hormone
-
TTF1
-
thyroid transcription factor 1
-
TTP
-
time to progression
U
-
UFT
-
tegafur-uracil
-
UGT1A1
-
UDP-glucuronosyltransferase 1A1
-
ULN
-
upper limit of normal
-
UPA
-
urokinase-type plasminogen activator
-
UPGT
-
uridine diphosphate glucuronosyltransferase
-
UPS
-
ubiquitin proteasome pathway
V
-
VATS
-
video-assisted thoracoscopic surgery
-
VCAM
-
vascular cell adhesion molecule
-
VCAM-1
-
vascular cell adhesion molecule-1
-
VCR
-
vincristine
-
Vd
-
volume of distribution
-
VDT
-
volume doubling time
-
VEGF
-
vascular endothelial growth factor
-
VEGFR
-
vascular endothelial growth factor receptor: They are a target for some cancer drugs.
-
VHL
-
Von Hippel-Lindau
-
VLP assay
-
virus-like particle assay
-
VM26
-
teniposide
-
Vmax
-
maximum disappearance rate
-
VOD
-
veno-occlusive disease
-
VP16
-
etoposide
-
VTA
-
vascular-targeting agent
-
VTE
-
venous thromboembolic event
W
-
WBC
-
white blood cell
-
WBRT
-
whole brain radiotherapy
-
WCRF
-
World Cancer Research Fund
X
-
XAF1
-
XIAP-interacting protein 1
-
XL184
-
cabozantinib
-
XRCC1
-
X-ray repair cross-complementing group 1
Y
-
YACs
-
yeast artificial chromosomes